Dr. Petros Grivas
Claim this profileFred Hutch/University of Washington Cancer Consortium
Area of expertise
Bladder Cancer
Petros Grivas has run 5 trials for Bladder Cancer. Some of their research focus areas include:
Transitional Cell Carcinoma
Petros Grivas has run 2 trials for Transitional Cell Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
Fred Hutch/University Of Washington Cancer Consortium
University Of Washington Medical Center - Montlake
Clinical Trials Petros Grivas is currently running
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting
1 award
Phase 2
10 criteria
Pre-Surgery Sacituzumab Govitecan
for Bladder Cancer
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan before radical cystectomy may make the surgery more effective in patients with muscle invasive bladder cancer.
Recruiting
1 award
Phase 2
20 criteria
More about Petros Grivas
Clinical Trial Related
3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Petros Grivas has experience with
- Gemcitabine
- Sacituzumab Govitecan
- Cisplatin
- Avelumab
- Combination Chemotherapy
- Pembrolizumab
Breakdown of trials Petros Grivas has run
Bladder Cancer
Transitional Cell Carcinoma
Urothelial Carcinoma
Myelosuppression
Low White Blood Cell Count
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Petros Grivas specialize in?
Petros Grivas focuses on Bladder Cancer and Transitional Cell Carcinoma. In particular, much of their work with Bladder Cancer has involved Stage IV patients, or patients who are Stage III.
Is Petros Grivas currently recruiting for clinical trials?
Yes, Petros Grivas is currently recruiting for 3 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Petros Grivas has studied deeply?
Yes, Petros Grivas has studied treatments such as Gemcitabine, Sacituzumab Govitecan, Cisplatin.
What is the best way to schedule an appointment with Petros Grivas?
Apply for one of the trials that Petros Grivas is conducting.
What is the office address of Petros Grivas?
The office of Petros Grivas is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.